These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Severely contracted bladder following intravesical bacillus Calmette-Guérin therapy]. Yoshimura K; Saiki S; Kuroda M; Kiyohara H; Kotake T Nihon Hinyokika Gakkai Zasshi; 1988 Nov; 79(11):1848-51. PubMed ID: 3216568 [No Abstract] [Full Text] [Related]
10. Cytological, histological, and clinical correlations in intravesical Bacillus Calmette-Guerin immunotherapy. Bhan R; Pisharodi LR; Gudlaugsson E; Bedrossian C Ann Diagn Pathol; 1998 Feb; 2(1):55-60. PubMed ID: 9845722 [TBL] [Abstract][Full Text] [Related]
11. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment. Yates J; Stein B Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061 [TBL] [Abstract][Full Text] [Related]
12. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer. Demkow T; Alter A; Wiechno P Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238 [TBL] [Abstract][Full Text] [Related]
13. Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report. Merguerian PA; Donahue L; Cockett AT J Urol; 1987 Feb; 137(2):216-9. PubMed ID: 3492613 [TBL] [Abstract][Full Text] [Related]
14. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
15. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
16. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445 [TBL] [Abstract][Full Text] [Related]
18. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors. Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563 [TBL] [Abstract][Full Text] [Related]
19. Renal complications of intravesical bacillus Calmette-Guérin therapy. Modesto A; Marty L; Suc JM; Kleinknecht D; de Frémont JF; Marsepoil T; Veyssier P Am J Nephrol; 1991; 11(6):501-4. PubMed ID: 1819218 [TBL] [Abstract][Full Text] [Related]
20. Impact of bacillus Calmette-Guerin intravesical therapy on the diagnostic efficacy of The Paris System for Reporting Urinary Cytology in patients with high-grade bladder cancer. Hermans J; Jokisch F; Volz Y; Eismann L; Pfitzinger P; Ebner B; Weinhold P; Schlenker B; Stief CG; Tritschler S; Schulz GB Cancer Cytopathol; 2022 Apr; 130(4):294-302. PubMed ID: 34919338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]